Publication number:

0 258 045

1

### **EUROPEAN PATENT APPLICATION**

2 Application number: 87307537.8

22 Date of filing: 26.08.87

(5) Int. Cl.4: **A 61 D 1/02** A 61 K 39/012

39 Priority: 28.08.86 US 901912

Date of publication of application: 02.03.88 Bulletin 88/09

Designated Contracting States:
BE CH DE ES FR GB GR IT LI LU NL SE

Applicant: ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis Indiana 46285 (US)

(2) Inventor: Bafundo, Kenneth William 5893 Forrest Lane Indianapolis Indiana 46220 (US)

> Jeffers, Thomas Kirk 1303 Bittersweet Drive Greenfield Indiana 46140 (US)

Representative: Hudson, Christopher Mark et al Eri Wood Manor Windlesham Surrey GU20 6PH (GB)

Method of improving the quality of animals.

The present invention is directed to a method for improving the quality of a coccidiosis-susceptible animal which comprises

(1) orally administering to the animal, at the neonate stage, infective coccidial organisms in a number effective to generate an immunological response by the animal, while

(2) maintaining the animal free of any chemotherapeutic anticoccidial for a period beginning with birth or hatching and continuing after step (1) until sporozoites have penetrated host cells, and

(3) thereafter administering an ionophore substantially continuously throughout the life of the animal.

EP 0 258 045 A2

#### Description

10

20

25

30

35

# METHOD OF IMPROVING THE QUALITY OF ANIMALS

The present invention relates to methods of improving the quality of animals susceptible to coccidiosis. U.S. Patent 4,544,548 discloses a method of continuous administration of oocysts to poultry.

We have now discovered that the quality of an animal susceptible to coccidiosis, with respect to its growth, feed utilization or appearance, can be improved by initial administration of oocysts followed by an ionophore. The present Invention is directed to a method for improving the quality of a coccidiosis-susceptible animal which comprises

(1) orally administering to the animal, at the neonate stage, infective coccidial organisms in a number effective to generate an immunological response by the animal, while

(2) maintaining the animal free of any chemotherapeutic anticoccidial for a period beginning with birth or hatching and continuing after step (1) until sporozoites have penetrated host cells, and

(3) thereafter administering an ionophore sustantially continuously throughout the life of an animal.

The animals most susceptible to coccidiosis are the various fowl. Accordingly, a preferred embodiment of the present Invention is the practice of the above method with fowl.

The use of the ionophore anticoccidials with fowl has been unusually successful, because only a very small number of strains of Eimeria (the protozoan pathogen which causes coccidiosis) exhibit reduced sensitivity or resistance to the ionophores. However, even this limited incidence of resistance presents a problem to the poultry industry. In addition to the loss in terms of reduced weight gain, poorer feed efficiency, and the like, coccidiosis of even a mild form can interfere with the uptake of pigmentation. The result is a bird that fails to meet the consumer's expectation for appearance. It is an advantage of the method of the invention that it can give improvements in weight gain and in the bodily appearance of the bird even when resistant strains of Eimeria are present.

Furthermore, it has been discovered that this control of resistant strains can be achieved by the administration of strains of Eimeria which are ionophore-sensitive, thereby minimizing the risk of further spread of resistance. Thus, in an especially preferred embodiment, the present invention is directed to a particular method of improving the quality of a fowl susceptible to coccidiosis from an ionophore-resistant strain of Eimeria which comprises

(1) orally administering to the fowl, within 24 hours of hatching, an effective number of infective organisms of an ionophore-sensitive strain of Eimeria which is capable of conferring immunity against the ionophore-resistant strain of Eimeria, while

(2) maintaining the fowl free of any chemotherapeutic anticoccidial for a period beginning with hatching and continuing after step (1) until sporozoites have penetrated host cells, and

(3) thereafter administering an anticoccidially effective dose of an ionophore substantially continuously throughout the life of the fowl.

The ionophores are a class of antibiotics of complex structure; from their inclusion of multiple oxygen atoms, they are also known as polyethers. Many members of this class are already known, and others are from time to time discovered. All ionophores exhibit anticoccidial activity, although the relative degree of such activity varies from ionophore to ionophore, and occasionally the toxicity of a particular ionophore may make its utilization as an anticoccidial impractical. Among the ionophores which have achieved significance for the commercial control of coccidiosis are monensin, narasin, lasalocid, and salinomycin. Any of these lonophores can be employed in the present invention. Other representative ionophores that can be used in the present invention include laidlomycin, nigericin, grisorixin, dianemycin, lenoremycin, lonomycin, antibiotic X206, alborixin, septamycin, antibiotic A204, etheromycin, isolasalocid, lysocellin, antibiotic A23187, maduramicin, A80190, and A80438.

The present improved method can be employed in any animal susceptible to coccidiosis. Although. warm-blooded animals of all sorts are susceptible to coccidiosis, the fowl suffer most from coccidiosis; therefore, chemotherapeutic treatment by one of the ionophores is nearly universal. Chickens and turkeys are the species most commonly needing protection against coccidiosis, and because of their economic importance, the present invention is most useful for these species. However, the present invention can also be practiced with other species of fowl, such as duck, geese, quail, pheasants, and the like. Warm-blooded animals other than fowl are sometimes protected against coccidiosis by use of the same ionophores utilized with fowl. The present improved method can therefore be used with such other species, such as cattle, sheep, swine, and the like.

The present invention is carried out by administering infective coccidial organisms to an animal susceptible to coccidiosis. The administration is carried out at the neonate stage, shortly after birth or hatching. In general, the administration will be carried out within the first 24 hours from birth or hatching. In typical poultry practices, each fowl is handled shortly after hatching, generally within the first 6 to 12 hours after hatching. In this handling, the fowl is typically debeaked, and vaccinated against various diseases, notably Marek's disease, infectious bronchitis, Newcastle's disease, and the like. In other poultry species, the birds are not handled individually or debeaked, but are nonetheless treated at this neonate stage by exposure to an aerosol which delivers the necessary vaccines against the same disease.

It has been found that the present invention can conveniently be practiced as part of these standard

procedures, and indeed, that certain time relationships must be observed to obtain the benefits of the present invention. Various references suggest that a newly hatched fowl is incapable of a full immunogenic response. However, the inventors have found that vaccination at the neonate stage is indeed effective, and, when employed in conjunction with the earliest possible use of ionophores consistent with the immunological process, provides superior control of coccidiosis.

In accordance with the present invention, infective coccidial organisms are administered to the animal to be protected against coccidiosis. The exact form of the organisms is not critical, so long as the form is one which will generate an immunological response by the animal. Suitable forms of infective coccidial organisms include sporulated oocysts, sporozoites, and sporocysts. Both of the latter forms require additional workup, and sporozoites are relatively unstable. Generally, the preferred form will be sporulated oocysts. The preparation of suspensions of various forms of infective coccidial organisms is well known to those skilled in the art. A representative preparation of sporulated oocysts is shown below in Example 1.

10

30

It is important that the infective coccidial organisms be administrated orally. Again, the objective is an immunological response by the animal, and administration by other routes is less certain to engender the necessary immunological response. Oral administration is also desirable in that the precise number of infective organisms can be controlled. For these various reasons, the present invention is generally practiced by spraying a suspension containing the necessary coccidial organisms directly into the animal's mouth. However, in accordance with other practices described above, oral administration can also be achieved by aerosol delivery. It is known that aerosol delivery is an indirect mode of delivery to the mouth cavity. Material which the bird absorbs from an aerosol ocularly or nasally will in part drain to the mouth cavity; also, material deposited from an aerosol onto the bird's feathers will, by means of preening, also arrive at the bird's mouth cavity. Therefore, although the present invention is directed to oral administration, this term includes aerosol delivery which inevitably becomes an oral administration.

Although it is possible that the infective organisms can be administered in more than one dose, there is no advantage to multiple dosings, and multiple dosings have the effect of delaying ionophore therapy. In practice, one single dose is much preferred.

The exact number of infective coccidial organisms to be administered is not critical except that the number must be effective to engender an immunological response by the animal. In general, an immunological response can be obtained when using from 1 to 100,000 occysts. The exact number can be determined by those of ordinary skill in the art, by the use of simple range-finding experiments. The exact number will vary with the species and size of the particular animal, the relative immunogenicity of the particular strain which is sought to be controlled, whether the strain is a wild strain or an attenuated strain, and other factors known to those skilled in the art. In many cases, good results are obtained in fowl with single doses of from about 10 to about 5,000 occysts of Eimeria maxima or Eimeria tenella, and with single doses of from about 50 to about 20,000 occysts of Eimeria acervulina. In some situations, doses of from 1,000 to 5,000 occysts of Eimeria maxima and Eimeria tenella, and from 5,000 to 10,000 occysts of Eimeria acervulina will suffice.

In a preferred embodiment, the present invention is used to give quality improvements in animals susceptible to Eimeria strains which are not controlled by the ionophores. In this embodiment, the present invention provides better anticoccidial protection than is possible by the use of the ionophores, alone. A number of strains of Eimeria are known to exhibit reduced sensitivity, or even outright resistance, to the ionophores. In the use of the present invention for the control of such strains, the immunizing dose of infective coccidial organisms can be of the very strain sought to be controlled, that is, the strain exhibiting reduced sensitivity or resistance. However, the propagation of ionophore-resistant organisms runs the risk of increasing the incidence of such organisms in the general Eimeria population. It is therefore preferred to use an ionophore-sensitive strain which will confer immunity against the ionophore-resistant strain. In general, different strains of the same species will confer immunity against other strains of the same species. However, this is not universally true, so that in practice, it will be appropriate to determine whether a particular ionophore-sensitive strain is, indeed, capable of conferring immunity against the ionophore-resistant strain sought to be controlled.

This can be determined by simple preliminary tests easily within the skill of the ordinary artisan. Generally, the test is conducted by administering the candidate ionophore-sensitive strain, withholding all anticoccidial chemotherapy, and shortly thereafter, such as from 5 to 20 days, challenging the birds with the ionophore-resistant strain sought to be controlled. The birds are then sacrificed and the usual parameters of coccidiosis disease evaluated. However, it is also possible to follow the immunological response of the birds by ascertaining the levels of antibodies. By these techniques, one can determine in a small scale test whether a particular ionophore-sensitive strain of Eimeria will confer immunity on the ionophore-resistant strain sought to be controlled.

After the step of administering the infective coccidial organisms, it is necessary that there be a delay until administration of lonophore is begun. The function of the delay is to permit the immunological process to proceed, uninterrupted. The delay must therefore be long enough to permit the infective coccidial organisms to travel to the relevant section of the intestinal tract and invade host cells, after which the immunological process will proceed because the intracellular organisms are protected from ionophore therapy. The exact number of hours of delay will vary with the identity of the host and the rate of transit through the gastrointestinal tract; and with the particular species of coccidium and the location of the gastrointestinal tract which it infects. Much is known by those skilled in the art concerning normal transit times through the

gastrointestinal tract, the site of infection by the various coccidial species, and the like. In chickens, this delay should be on the general order of one to four hours. In cattle, it is expected that the delay will be on the order of 4-8 hours. It is possible to delay chemotherapeutic treatment for an even longer time period, such as up to 24 hours. However, further delay leaves the animal unprotected from coccidiosis, except as has been provided by the immunological process, and is therefore undesirable. The preferred practice, therefore, is to delay ionophore therapy only as long as the time required for sporozoites to penetrate host cells.

Following this delay period, ionophore is administered and is employed substantially continuously throughout the life of the animal. As noted above, many of the ionophores are used commercially for the control of coccidiosis. Those of ordinary skill in the art are therefore well acquainted with the techniques for their use, the amounts thereof which are effective to control coccidiosis, and the like, so that a detailed discussion is not needed. Effective anticoccidial amounts for several of the ionophores, expressed in terms of the concentration in the feedstuff, are

monensin 80 to 125 ppm narasin 50 to 80 ppm lasalocid 75 to 125 ppm salinomycin 40 to 70 ppm maduramicin 4 to 8 ppm A80190 10 to 40 ppm

15

Although the ionophore is to be administered substantially continuously throughout the life of the animal, occasional interruptions and pre-slaughter withdrawal do not alter the advantages of the present invention.

Typically the ionophore therapy required by the present invention will be achieved by using a single ionophore as the sole anticoccidial agent. However, it is entirely possible to use a mixture of two ionophores, in which case the amounts of each will be reduced.

All of the foregoing teaching is based on present conventional practices for the rearing of animals, especially those practices for the rearing of poultry, which suffer the most from coccidiosis. However, the present invention is also adapted to be employed in conjunction with newly emerging technology for the embryonic immunization of poultry. Attention is directed to U.S. Patent 4,458,630, and to Avian Diseases 26(1):134-149, 1982. In embryonic immunization, an immunizing substance is injected into avian eggs. The present invention can be adapted for use in conjunction with embryonic immunization. In this adaptation, the immunization necessary to the present invention is carried out in accordance with U.S. Patent 4,458,630, except that it is not believed to be necessary for the present invention that occysts be injected into the amnion or the yolk sac. Rather, it is believed that embryonic immunization against coccidiosis can also be achieved by injection into the chorioaliantoic cavity.

After hatching, the practice of the present invention is the same, that is, an anticoccidially effective dose of an ionophore is administered substantially continuously throughout the life of the bird. However, the exact timing of immunological response to embryonic immunization is not known with certainty; the response may in fact be delayed until hatching, when the yolk sac is absorbed and becomes a part of the intestinal tract of the bird. Furthermore, the immunological response may vary some from egg to egg, depending on the exact site of injection. Therefore, to assure maximum response to embryonic immunization, the ionophore therapy is preferably delayed, even as in the main embodiment of the present invention. With embryonic immunization, the delay period should be determined by the same factors discussed above, but calculated as if hatching were the point of exposure to infective coccidial organisms.

In this adaptation, then, the present invention is directed to a method for protecting a fowl against coccidiosis which comprises

(1) during the final quarter of an incubation period of an avian egg comprising an embryo, injecting the egg with infective coccidial organisms in a number effective to generate an immunological response, and

(2) following hatching, administering an anti-coccidially effective dose of an ionophore substantially continuously throughout the life of the fowl.

In this adaptation of the present invention as in the general practice of the invention, another preferred embodiment is the use of an ionophore sensitive strain of <u>Eimeria</u> to protect against an ionophore resistant strain of Eimeria.

The present invention is illustrated by the following non-limiting examples.

#### Example 1

45

50

#### Preparation of Sporulated Oocyst Suspension

#### Source

A suspension of sporulated oocysts suitable for carrying out the present invention was prepared as described below.

The coccidial strain employed was <u>Eimeria maxima FS-177</u>, which was originally isolated in 1974 from Perdue Farms, Inc., Salisbury, MD. Since its isolation, it has been maintained by passage through chickens. The strain is ionophore sensitive. This strain is available without restriction from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA, under the ATCC designation Number 40357 (deposited August 7, 1987).

**Production of Oocysts** 

An infectious inoculum was prepared by diluting a stock suspension of sporulated oocysts to the appropriate concentration (15,000-50,000 oocysts/ml) with tap water.

Birds were inoculated with the culture via crop intubation using a syringe. Between 15,000 and 50,000 Eimeria maxima oocysts were administered to each bird in not more than 1 ml of solution.

.5

15

20

35

45

50

55

60

The birds were housed in steam-sterilized battery cages for eight days post infection. Other special precautions were employed. The birds were monitored for the eight-day prepatent period. Fecal material was microscopically examined for the presence of occysts other than Elmeria maxima. In addition, the intestinal tracts of all birds were later examined for the presence of lesions produced by other coccidial species (Johnson and Reid, 1970).

On the seventh and eighth days post infection, the feces from these birds were collected and blended with tap water to obtain a homogeneous suspension of occysts.

Workup

This suspension was strained through a fine mesh screen so that all particulate material was removed. The resultant suspension was then added to an equal volume of saturated NaCl in order to separate the occysts from the remaining fecal debris (although NaCl was used in this workup, any other additive which creates a high viscosity solution can be used instead of NaCl; other additives commonly employed are sucrose and ZnSO<sub>4</sub>). The occysts floated to the surface of the NaCl solution and were collected via aspiration. The occysts were then washed free of the saturated salt by repeated low-speed centrifugation. (Large quantities of purified occysts may be produced via continuous flow centrifugation, see Vetterling, J. M., J. Parasitol. 55:412-417, 1969.)

A concentrated aggregate of oocysts produced as described above was mixed into 2% K<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub> (potassium dichromate) to cause the oocysts to sporulate. The number of sporulated oocysts in a solution was determined microscopically by counting the number of infective organisms which appeared on the grid of a hemacytometer. When the number of sporulated oocysts/mi had been determined, dilutions with 2% K<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub> were made to the desired concentration of sporulated oocysts/mi. Determinations of purity and potency were performed by microscopic examination of oocyst morphology. The number of sporulated oocysts/mi in each lot was verified.

#### Example 2

The Effect of Day-Old Immunization With Elmeria maxima on the Response to Challenge Infection at 10 Days of Age

A battery experiment was performed with Hubbard chicks to evaluate the effects of day-old immunization with Eimena maxima (FS-177 strain) on the response to challenge by the same species and strain at ten days of age. No ionophore was employed in this experiment.

Hubbard-White Mountain cockerels were used in this experiment. Immediately after delivery from the hatchery, birds were weighed and assigned to treatment groups. Each treatment was replicated five times and each replicate contained four chicks. Chicks were fed a standard broiler starter ration for the duration of the experiment. The treatments used in the study were:

- 1. Nonimmunized, nonchallenged.
- 2. Nonimmunized, challenged on day 10.
- 3. Immunized day 0, challenged on day 10.

Immunized birds were orally inoculated with 2,000 Eimeria maxima oocysts on day 0. The inoculation was with a suspension of sporulated oocysts prepared as described in Example 1. Those groups which were challenged were orally administered 50,000 Eimeria maxima (FS-177 strain) oocysts/bird on day 10.

Seven days after the administration of the challenge inoculum, all birds were weighed, bled via cardiac puncture and lesion scored (J. Johnson and W. M. Reid, Exp. Parasitol. 28:30-36, 1970). Serum was prepared from each blood sample and analyzed for  $\beta$ -carotenoid equivalents (Ruff et al., Poultry Sci. 53:1801-1809, 1974). In addition, feces from all groups were collected on days 6 and 7 post challenge. From this material, average occyst production per bird was ascertained.

The results of this trial are presented in Table 1. Challenge infection administered on day 10 produced significant reductions in performance and  $\beta$ -carotenoid equivalents of birds not protected by immunization on day 0. This was accompanied by a severe mean intestinal lesion score and an oocyst output over 40 million/bird.

Birds immunized with 2,000 <u>Eimeria maxima</u> oocysts on day 0, however, experienced significant improvement in feed conversion and numerical increases in weight gain when compared to nonimmunized/challenged birds. Likewise, lesion scores and oocyst output were dramatically reduced by the immunization regimen and, as a result, serum pigmentation was statistically equivalent to the nonimmunized, nonchallenged controls.

The results of this study indicate that the day-old chick is capable of mounting a protective immune response after an initial immunizing dose of 2,000 sporulated Eimeria maxima oocysts. This protective effect was observed in performance, lesion scores, oocyst output and serum β-carotenoid equivalents seven days

,		
10		
15		
20		
25		
30		
35		
40		
45		•
<i>50</i>		
<i>55</i>		

60

65

Parameters of Coccidiosis1/

Group	% Mortality	Average Weight Gain	F/G	Lesion Scores (0=none, 4=maximum)	Total oocysts/bird	Serum β-carotenoid equivalents (us/ml)
Nonimmunized, nonchallenged	<b>8</b> 0 /	385.7 <sup>8</sup>	1.574 <sup>b</sup>	50	q <sup>0</sup>	5.23ª
Nonimmunized, challenged on day 10	9 g	287.7 <sup>b</sup>	1.911 <sup>8</sup>	6.00 <sup>8</sup>	42,430,000 <sup>8</sup>	1,09 <sup>b</sup>
Immunized, challenged on day 10	0 9	314.9 <sup>b</sup>	1.660 <sup>b</sup>	0.65 <sup>b</sup>	900,000	4, 13 <sup>a</sup>

 $^{1\prime}$  Means within columns not followed by a common letter are significantly different P<0.05.

#### Example 3

The Effect of Day-Old Immunization With Elmeria maxima on the Response to Challenge at 21 Days of Age, in Conjunction with Monensin

5

A floor pen study was conducted with Hubbard straight-run chickens to assess the effects of day-old immunization with <u>Eimeria maxima</u> strain FS-177 on the response to challenge by <u>Elmeria maxima</u> FS-410 (an ionophore resistant strain) at 21 days of age. In addition, the effects of monensin (100 ppm) on these immunization schemes were determined in a complete 2 × 2 factorial design.

10

The results of this experiment indicate that oral immunization (2,000 Eimeria maxima strain FS-177 oocysts) protected birds from challenge of Eimeria maxima strain FS-410 at 21 days when lesion scores and serum pigmentation were evaluated. This phenomenon occurred in both the presence and absence of 100 ppm of monensin.

Hubbard-white Mountain straight-run chickens were used in this test. Immediately after delivery from the hatchery birds were randomly assigned to treatment groups. Each treatment was replicated four times and contained 50 birds per replicate. Chicks were fed a standard broiler starter ration which contained either 0 or 100 ppm monensin for the duration of the experiment. The treatments used in this study were:

15

- 1. Nonmedicated, nonimmunized.
- 2. Nonmedicated, immunized (2,000 Eimeria maxima strain FS-177 oocysts).
- 3-4. As 1-2 with 100 ppm monensin incorporated into broiler feed.

20

Immunized birds were orally inoculated with 2,000 Eimeria maxima (FS-177) oocysts approximately four hours before they were fed either the nonmedicated ration or the medicated ration. The inoculation was with a suspension of sporulated oocysts prepared as described in Example 1. All birds were challenged on day 21 by spreading infectious litter containing oocysts of Eimeria maxima (FS-410) over the existing litter in the floor pen. Seven days post challenge, all birds were weighed and sacrificed, and 15 birds per replicate were chosen at random for lesion scoring and serum pigmentation analysis. The techniques of Johnson and Reid (Exp. Parasitol. 28:30-36, 1970) were used to evaluate lesion scores, while the methods of Ruff et al., (Poultry Sci., 53:1801-1809, 1974) were employed in pigmentation analyses.

25

Data were analyzed using analysis of variance (ANOVA) procedures; in some cases differences between treatment means were determined using Student-Newman-Keul's test (P<0.05).

30

The results of this study are presented in Table 2. Birds immunized with 2,000 Eimeria maxima occysts were protected from challenge infection (FS-410) at 21 days of age when lesion scores and serum pigmentation were evaluated. Similar trends were observed in immunized birds which were fed monensin.

35

The results of this study indicate that immunized chicks raised in floor pens mount an immune response which is capable of protecting them from the adverse effects of an ionophore resistant challenge at 21 days of age. Significant improvements in lesion scores and serum pigmentation illustrate the protective effects of oral immunization on the first day of life.

40

45

50

55

-60

Table 2

The Effect of Day-Old Immunization with Eimeria maxima FS-177 on Response to Challenge by Eimeria maxima FS-410 at 21 Days of Age in Floor Pens

Results1/

100 ppm  Average				Monensin Concentration	ncentration	-	
Ave.Average Wt.β-carotene equivalents (µg/ml gainAverage (µg/ml (g)Average (µg/ml (g)Gain (g)Lesion (g)Lesion Score970a 970a2.90a 2.45b2.45b 943a943a 2.03a978a 978a0.80b 3.96a3.96a 950a0.93b			mdd O			100 ppm	
Wt.Intestinal Gainequivalents ( $\mu g/ml$ )Wt.Intestinal Lesion(8)Scoreof serum)(g)Score $970^a$ $2.90^a$ $2.45^b$ $943^a$ $2.03^a$ $978^a$ $0.80^b$ $3.96^a$ $950^a$ $0.93^b$		Ave.	Average	β-carotene	Ave.	Average	β-carotene
Gain         Lesion         (µg/ml)         Gain         Lesion           (8)         Score         of serum)         (g)         Score           970 <sup>a</sup> 2.90 <sup>a</sup> 2.45 <sup>b</sup> 943 <sup>a</sup> 2.03 <sup>a</sup> 978 <sup>a</sup> 0.80 <sup>b</sup> 3.96 <sup>a</sup> 0.93 <sup>b</sup>		Wt.	Intestinal	equivalents	¥t.	Intestinal	equivalents
(8) Score of serum) (g) Score 970 <sup>a</sup> 2.90 <sup>a</sup> 2.45 <sup>b</sup> 943 <sup>a</sup> 2.03 <sup>a</sup> 978 <sup>a</sup> 0.80 <sup>b</sup> 3.96 <sup>a</sup> 950 <sup>a</sup> 0.93 <sup>b</sup>		Gain	Lesion	(µ8/m]	Gain	Lesion	(µ8/m]
$970^{a}$ $2.90^{a}$ $2.45^{b}$ $943^{a}$ $2.03^{a}$ $978^{a}$ $0.80^{b}$ $3.96^{a}$ $950^{a}$ $0.93^{b}$	sation	(g)	Score	of serum)	(g)	Score	of serum)
978 <sup>a</sup> 0.80 <sup>b</sup> 3.96 <sup>a</sup> 950 <sup>a</sup> 0.93 <sup>b</sup>		970 <sup>a</sup>	2.90ª	2.45 <sup>b</sup>	943a	2.03 <sup>a</sup>	3.43ab
	10	978 <sup>a</sup>	0.80 <sup>b</sup>	3.96ª	950 <sup>a</sup>	0.93 <sup>b</sup>	3.98ª

1' Means within columns not followed by a common letter are significantly different P<0.05.

## ANOVA - One Way

	=====		<del>nuy</del>		
					5
Source	SS	DF	MS	F-Ratio	
Treatment Error	10.2744 6.8794	5 <u>18</u>	2.0548 0.3821	5.376	10
Total	17.1539	23			
(Pooled standard error of and 0.31, respectively.)	of the mean for weight g	ain, lesion sco	res, and β-carotene equi	valents were 12.6, 0.26,	15
Example 4					
Conjunction with Mone	nsin		n the Response to Con		20
immunization with Eime shortly after immunizati experiment reported in	ria maxima FS-177 on the challenge was Example 3. In addition	ne response to provided by re , the effects of	nt-run chickens to asses challenge by <u>Eimeria ma</u> eusing the same floor p i levamisole administrati also evaluated in a 3 × 3	xima FS-410 beginning ens and litter from the on in drinking water (5	<i>25</i>
The results of the st challenge at 1 day of a pigmentation indicated immunization on lesion	ge when weight gain w hat the challenge in the scores and serum pig	as analyzed. Ir litter may have mentation.	on with Eimeria maxima consistent results in les been insufficient to fully	sion scores and serum evaluate the effects of	. <i>30</i>
from the hatchery, birds times and contained 50% the test. The treatment 1. Nonmedicated 2. Nonmedicated	were randomly assignormly assi	ned to treatme ks were fed a s ere: ria maxima FS-	e used in this study. Immore groups; each treatment and ard broiler starter restandard broiler starter restarter restandard broiler starter restarter restart	ent was replicated four ation for the duration of	35
weight) days 4, 5 an 4-6. As 1-3 with 1 immunized birds wer hours before being pla suspension of sporulate enhance the immune re- mg/kg body weight. The	d 6 in drinking water.  O ppm monensin incorn  o orally inoculated with  ced on either the med  d oocysts prepared as  sponse, was mixed into	porated into fee 2000 Eimeria licated or non described in E drinking wate		sts approximately four noculation was with a substance reported to at a concentration of 5	40 45
according to the proced analyzed for β-carotenoi was completed and per Data were analyzed evaluated using Studen	tures of Johnson and R d equivalents (Ruff et a formance criteria were using analysis of varia t-Newman-Keul's test	eid (Exp. Paras I., Poultry Sci. determined. nce (ANOVA) (P<0.05).	om, bled via cardiac pund sitol. 28:30-36, 1970). Se 53:1801-1809, 1974). On differences between t	rum was prepared and day 28 the experiment reatment means were	50
performance when com	pared to nonimmunize n pigmentation values	d, nonmedicate were inconsist	inization produced signi ed controls. Generally, i ent and demonstrated i	esion scores were not	<i>55</i>

60

Table 3

The Effect of Day-Old Immunization with Bimeria maxima on the Response to Continuous Challenge in Floor Pens<sup>1</sup>

			Monensin Concentration	entration		
,	-	mdd 0			100 ppm	
Immunization	Wt. Gain (g)	Lesion	B-CE <sup>2</sup>	Wt. Gain (g)	Lesion Score	B-CE <sup>2</sup>
None	738 <sup>b</sup>	0.12ª	4.348C	8068	0.25 <sup>a</sup>	4.51 <sup>ab</sup>
Oral <sup>3</sup>	786 <sup>a</sup>	0.00°	3.39 <sup>c</sup>	8048	0.25 <sup>a</sup>	5.26 <sup>a</sup>
Oral + Levamisole4	814 <sup>a</sup>	0.50ª	3.55 <sup>bc</sup>	794a	0.25 <sup>a</sup>	4.86 <sup>8</sup>

1 Means within columns not followed by a common letter are significantly different. Each treatment contained four replicates of 50 straight-run chicks. Lesion scores and blood parameters were collected on day 21.

 $^2\ \beta\mbox{-carotenoid}$  equivalents in  $\mu\mbox{g/ml.}$ 

3 Oral immunization contained 2,000 Eimeria maxima oocysts on day 0.

4 Oral + levamisole treated birds were immunized with 2,000 Eimeria maxima oocysts on day 0 and given levamisole (5 mg/kg body weight) in the drinking water on days 4, 5 and 6 of the experiment.

# ANOVA - One Way

					5
Source	SS	DF	MS	F-Ratio	
Treatment Error	10.6672 5.3336	5 18	2.1334 0.2963	7.199	10
Total	16.0009	23			
(Pooled standard error and 0.27, respectively.	of the mean for weight g )	gain, lesion sco	res, and β-carotene eq	uivalents were 27.7, 0.24,	15
Example 5					
pen. There were inten- nonimmunized, no	udy was conducted in who ded to be four treatment conmedicated		nent consisted of eight	pens, with 130 birds per	20
	edicated edicated with monensin ated with monensin, 12			·.	25
However, because of a ppm). Thereafter, the b	mixing error, for the first pirds were treated exactly his study was done at a le	st 21 days of th y as listed abov	e. The trial was carried	edicated (monensin, 120 d through an entire grow trains of <u>Elmeria maxima</u>	
The immunizing ooc oocysts were administ Gainesville, GA 30501)	ysts were Eimerla maxii	O-Vac machinurs before the	e (sold by Beak-O-Va birds were placed on	bove in Example 1. The c, Inc., P. O. Box 715, feed.	30
(1) On day 16, 1 FS-410; seven da β-carotenoid equiv	ten birds/pen were remays later (day 23) the later (day 23) the later remained.	oved and chall birds were ble	enged with 50,000 ood d and sacrificed. Les	sion scores and serum	35
<ul><li>(3) On each of owere determined.</li><li>(4) At the end ocharacteristics weight</li></ul>	and feed conversion of the days 27, 34, 41, and 47, and 47, of the 47-day period, boo re determined for all rema	five birds/pen of ty weight, final aining birds.	were bled and serum f	carotenoid equivalents	40
scale of 0-4, with 0 = r equivalents* is abbrevia	al analyses were as set for lesions and $4 = a$ materials attended to "Serum $\beta$ -CE"; the olded standard error of the standard erro	ximum number he "Analysis of	of lesions. In the table Variance" statistical ar	ss. "Serum 8-carotenoid	45
					50
					30
					<i>55</i>
					60

<u>Table 4</u>

Data on Birds Challenged at Day 16, Sacrificed at Day 23

Treatment*	Lesion Scores	Serum β-CE (μg/ml)
Immunized + Monensin	2.25	2.39
Immunized + Monensin	2.17	2.37
Monensin	3.44	1.94
Monensin	3.46	1.73

<sup>\*</sup>A mean was calculated for each of the four groups prior to discovery of the mixing error.

## ANOVA (Lesion Scores)

Vos	<u>df</u>	<u>SS</u> .	MS	F	<u>P</u>
Total Trt Immunized (I) Monensin (M) (I × M) Error	31 3 1 1 28	26.200300 12.327325 12.3008000 0.0055125 0.0210125 13.872975	4.1091083 0.4954634	8.3 24.8269 <1 <1	<.001 <.001 NS NS

PSEM = 0.25

### ANOVA (Serum \$-CE)

SOV	<u>df</u>	SS	MS	F	P
Total	31	7.6563969			
Trt	3	2.5643344	0.8547781	4.7	<.01
Immunized (I)	1	2.3925781		13.16	<.005
Monensin (M)	1	0.1023781	•	<1	NS
$I \times M$	1	0.0693781		<1	NS
Error	28	5.0920625	0.1818594		

PSEM = 0.15

Table 5

Performance Data on Remaining
(Non Challenged) Birds at Day 21

	Body Weight	
Treatment	(lbs.)	Feed Conversion
Immunized + Monensin Monensin	1.273 1.277	1.458 1.465

## ANOVA (Body Weight, 21 Days)

sov	df	SS	MS	F	P
Total Trt	31	0.0111962 0.0001575		<1	NS
Error	30	0.0110387	0.000368		

PSEM = 0.005

## ANOVA (Feed Conversion, 21 Days)

SOV.	<u>df</u>	SS	<u>MS</u>	<u> </u>	<u>P</u>
Total Trt	31	0.0087122 0.0003445		1.235	NS
Error	30	0.0083677	0.0002789		

PSEM = 0.004

. And the Area of the

Table 6 .
Weekly β-Carotenoid Equivalents (μg/ml)

Treatment	Day 27	Day 34	Day 41	Day 47
Immunized + Monensin	17.32	19.26	25.44	27.96
Immunized	16.09	17.65	22.71	26.94
Monensin	15.73	, 18.19	24.63	28.42
Control	14.54	15.43	24.03	22.36

## ANOVA (Day 27)

SOV	<u>df</u>	SS	MS	<u> </u>	_ <u>P</u>
Total	31	427.35745			
Trt	3	31.575434	•		
Immunized (I)	1	19.797778		1.401	NS
Monensin (M)	1	11.773378		.833	NS
$I \times M$	1	0.004278		<1	NS
Error	28	395.78202	14.135072		

PSEM = 1.32

## ANOVA (Day 34)

SOV	<u>df</u>	SS	MS	<u> </u>	<u>P</u>
Total	31	262.029670			
Trt	3	62.433109	20.811036	2.919	.05
Immunized (I)	1	21.598878		3.03	.075
Monensin (M)	1	38.171953		5.35	.025
$I \times M$	1	2.6622781		<1	NS
Error	28	199.59656	7.1284486		

PSEM = 0.9

# ANOVA (Day 41)

SOV	<u>df</u>	SS	MS	F	P
Total Trt Immunized (I) Monensin (M) I × M Error	31 3 1 1 1 28	254.01399 31.679838 0.5253125 22.144513 9.0100125 222.33415	10.559946 7.9405054	1.329 <1 2.7888 1.1346901	NS NS NS

PSEM = 0.996

# ANOVA (Day 47)

SOV	<u>df</u>	SS	MS	F_	P
Total Trt Immunized (I) Monensin (M) I × M Error	31 3 1 1 28	498.2835 184.70868 33.763653 100.2174 50.727628 313.57482	11.199101	5.50 3.01 8.95 4.53	<.005 <.10 <.01 <.05

PSEM = 2.5

Table 7
Final Performance Data (47 Days)\*

·	Body	Final	Processing and Carcass Characteristics*:		
Treatment	Weight (lbs.)	Feed Conversion	Color % 1-2	Finish % 1-2	
Immunized + Monensin	4.632 <sup>b</sup>	1.953	92.05	100	
Immunized	4.755 <sup>a</sup>	1.956	94.45	100	
Monensin	4.651 <sup>ab</sup>	1.956	95.00	100	
Control	4.696 <sup>ab</sup>	1.977	87.00	98.9	

<sup>\*</sup> Means within columns not followed by a common letter are significantly different.

# ANOVA (Final Body Weight)

sov	<u>df</u>	<u>ss</u>	MS	<u>F</u>	<u>P</u>
Total	31	0.237622			
Trt	3	0.0682438	0.0227479		
Immunized (I)	1	0.0018911		<1	NS
Monensin (M)	1	0.0510401		8.44	<.01
$I \times M$	1	0.0153125		2.53	NS
Error	28	0.1693782	0.0060492	2,00	

PSEM = 0.03

<sup>\*\*</sup> Each processed bird was given a score ranging from 1-5 for color and finish, with 1-2 = very good to excellent and 3-4 = fair to good.

#### ANOVA (Final Feed Conversion)

sov	₫£	SS	MS	F	<u> </u>	5
Total Trt Immunized (I) Monensin (M) I × M Error	31 3 1 1 28	0.0112202 0.0029266 0.0011400 0.0010928 0.0006938 0.0082936	0.0009755	3.29 3.85 3.69 2.34	<.05 <.075 <.075 NS	10
PSEM = 0.006						
Claims						20

1. A method for improving the quality of a coccidiosis-susceptible animal which comprises

(1) orally administering to the animal, at the neonate stage, infective coccidial organisms in a number effective to generate an immunological response by the animal, while

(2) maintaining the animal free of any chemotherapeutic anticoccidial for a period beginning with birth or hatching and continuing after step (1) until sporozoites have penetrated host cells, and

(3) thereafter administering an ionophore substantially continuously throughout the life of the animal.

2. A method according to Claim 1 for improving the quality of a fowl susceptible to coccidiosis from an ionophore-resistant strain of <u>Eimeria</u> which comprises

(1) orally administering to the fowl, within 24 hours of hatching, an effective number of infective organisms of an lonophore-sensitive strain of Eimeria which is capable of conferring immunity against the lonophore-resistant strain of Eimeria, while

(2) maintaining the fowl free of any chemotherapeutic anticoccidial for a period beginning with hatching and continuing after step (1) until sporozoites have penetrated host cells, and

(3) thereafter administering an anticoccidially effective dose of an ionophore substantially continuously throughout the life of the fowl.

3. A method for improving the quality of a fowl which comprises

(1) during the final quarter of an incubation period of an avian egg comprising an embryo, injecting the egg with infective coccidial organisms in a number effective to generate an immunological response, and

(2) following hatching, administering an anticoccidially effective dose of an ionophore substantially continuously throughout the life of the fowl.

4. A method of Claim 3 employing infective coccidial organisms of a strain of Eimeria which is ionophore sensitive but which confers immunity against an ionophore resistant strain of Eimeria.

5. A method of any one of Claims 1 to 4, wherein the ionophore is monensin.

6. A method of any one of Claims 1 to 4, wherein the ionophore is lasalocid.

7. A method of any one of Claims 1 to 4, wherein the ionophore is narasin.

8. A method of any one of Claims I to 4, wherein the ionophore is salinomycin.

9. A method of any one of Claims 1 to 4, wherein the ionophore is maduramicin.

10. A method according to any one of the preceding claims wherein the animal being protected is a chicken or a turkey.

60

30

35

45

50

55

65

The west to the West of the State

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

# IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.